Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY 4.0International Journal of Molecular Sciences

The Role of Ubiquitination and Ubiquitin-like Modifications in the Oncogenic Fusion Protein BCR-ABL

  1. 1Department of Biochemistry and Molecular Biophysics, University of California San Diego, La Jolla, CA 92093-0367, USA
  2. 2UCSD Moores Cancer Center, University of California San Diego, La Jolla, CA 92093-0367, USA

Abstract

Chronic myeloid leukemia (CML) is driven by the BCR-ABL fusion oncoprotein, a constitutively active tyrosine kinase whose inhibition by tyrosine kinase inhibitors (TKIs) transformed disease management. However, kinase-domain mutations, persistent leukemic stem cells (LSCs), and kinase-independent survival mechanisms still limit durable treatment-free remission. Increasing evidence indicates that BCR-ABL is regulated not only by kinase activity but also by post-translational modifications (PTMs) determining protein stability, turnover, interactions, and degradation. In this review, we examine how ubiquitination, SUMOylation, NEDDylation, phosphorylation, and acetylation-associated chaperone regulation control BCR-ABL proteostasis. Ubiquitin-dependent regulation involves opposing activities of E3 ligases and deubiquitinating enzymes, while TRIM28-mediated SUMOylation and RAPSYN-mediated NEDDylation stabilize BCR-ABL by limiting p62-dependent autophagic and c-CBL-mediated degradation, respectively. Crosstalk among these pathways suggests an integrated PTM network governs BCR-ABL fate rather than independent modifications. These mechanisms may impact persistent CML populations, though direct evidence linking specific PTMs to LSC maintenance remains limited. Therapeutically, manipulating PTM-dependent proteostasis via deubiquitinase inhibition, SUMO/NEDD8 modulation, chaperone disruption, and targeted protein degradation can complement conventional kinase inhibition. Notably, BCR-ABL-directed proteolysis-targeting chimeras (PROTACs) demonstrate the feasibility of eliminating the fusion protein rather than solely suppressing its catalytic activity. Ultimately, PTM-dependent proteostasis represents a critical regulatory dimension and therapeutic vulnerability in CML. Defining the spatial, temporal, and disease-specific PTM landscape of BCR-ABL is essential to determine if selective stability manipulation can overcome resistance and deepen therapeutic responses.

Related

  1. BCAM-AKT2 fusion protein promotes unfolded protein response driven oncogenic signaling in SKOV3 epithelial ovarian cancer cell line
    Hala Khazem, Ravid Solomon Zemler, Liron Vardi David +5
    PLOS OnePeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationStatisticsPLOS
  2. Crosstalk between ubiquitination and other post-translational modifications in cardiovascular diseases.
    Yi Yan, Zhiqiang Li, Tingting Xiao
    ISciencePeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMC
  3. E3 ubiquitin ligase MAGI3-mediated TAZ ubiquitination suppresses the non-small cell lung cancer occurrence and development by targeting the Wnt pathway
    Ye Liang, Jie Zhuang
    International Journal of OncologyPeer-reviewedCC BY-NC-ND 4.0Full textMolecular biology & gene regulationPMC
  4. Lipid and Carbohydrate Modifications Enhance Potency of Antisense Oligonucleotides Targeting Oncogenic KRAS
    Faith Kivunga, Julien Verget, Helene Pereira +5
    Bioconjugate ChemistryPeer-reviewedCC BY-NC-ND 4.0Full textProteomics & metabolomicsGeneral biologyHAL
  5. A fish-specific E3 ubiquitin ligase NHRE3 suppresses antiviral immunity by degrading ISG15 via ubiquitination
    Juhong Xie, Jiayi Lei, Qinxue Zhu +4
    PLOS PathogensPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationPLOS
BibTeX
@article{shammas2026role,
  title = {{The Role of Ubiquitination and Ubiquitin-like Modifications in the Oncogenic Fusion Protein BCR-ABL}},
  author = {Tara Shammas and Daniel J. Donoghue},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  month = nov,
  doi = {10.3390/ijms272210231},
  url = {https://www.mdpi.com/1422-0067/27/22/10231},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - The Role of Ubiquitination and Ubiquitin-like Modifications in the Oncogenic Fusion Protein BCR-ABL
AU  - Tara Shammas
AU  - Daniel J. Donoghue
PY  - 2026
DA  - 2026/11/15
JO  - International Journal of Molecular Sciences
DO  - 10.3390/ijms272210231
UR  - https://www.mdpi.com/1422-0067/27/22/10231
AB  - Chronic myeloid leukemia (CML) is driven by the BCR-ABL fusion oncoprotein, a constitutively active tyrosine kinase whose inhibition by tyrosine kinase inhibitors (TKIs) transformed disease management. However, kinase-domain mutations, persistent leukemic stem cells (LSCs), and kinase-independent survival mechanisms still limit durable treatment-free remission. Increasing evidence indicates that BCR-ABL is regulated not only by kinase activity but also by post-translational modifications (PTMs) determining protein stability, turnover, interactions, and degradation. In this review, we examine how ubiquitination, SUMOylation, NEDDylation, phosphorylation, and acetylation-associated chaperone regulation control BCR-ABL proteostasis. Ubiquitin-dependent regulation involves opposing activities of E3 ligases and deubiquitinating enzymes, while TRIM28-mediated SUMOylation and RAPSYN-mediated NEDDylation stabilize BCR-ABL by limiting p62-dependent autophagic and c-CBL-mediated degradation, respectively. Crosstalk among these pathways suggests an integrated PTM network governs BCR-ABL fate rather than independent modifications. These mechanisms may impact persistent CML populations, though direct evidence linking specific PTMs to LSC maintenance remains limited. Therapeutically, manipulating PTM-dependent proteostasis via deubiquitinase inhibition, SUMO/NEDD8 modulation, chaperone disruption, and targeted protein degradation can complement conventional kinase inhibition. Notably, BCR-ABL-directed proteolysis-targeting chimeras (PROTACs) demonstrate the feasibility of eliminating the fusion protein rather than solely suppressing its catalytic activity. Ultimately, PTM-dependent proteostasis represents a critical regulatory dimension and therapeutic vulnerability in CML. Defining the spatial, temporal, and disease-specific PTM landscape of BCR-ABL is essential to determine if selective stability manipulation can overcome resistance and deepen therapeutic responses.
SN  - 1422-0067
ER  -